相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes
Yogen Saunthararajah et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Targeting FLT3 to treat leukemia
Heiko Konig et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2015)
Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
Yi-Bin Chen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Bone marrow stroma-mediated resistance to FLT3 inhibitors in FLT3-ITD AML is mediated by persistent activation of extracellular regulated kinase
Xiaochuan Yang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
Farhad Ravandi et al.
BLOOD (2013)
FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance
Michael R. Grunwald et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2013)
Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
Hubert Serve et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prolonged Treatment with DNMT Inhibitors Induces Distinct Effects in Promoters and Gene-Bodies
Yan-Fung Wong et al.
PLOS ONE (2013)
RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia
Josephine Aimiuwu et al.
BLOOD (2012)
Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITDAML
Amy Sexauer et al.
BLOOD (2012)
Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation
Cheuk Him Man et al.
BLOOD (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia
D. A. Pollyea et al.
LEUKEMIA (2012)
Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
Catherine C. Smith et al.
NATURE (2012)
p53-Independent, Normal Stem Cell Sparing Epigenetic Differentiation Therapy for Myeloid and Other Malignancies
Yogen Saunthararajah et al.
SEMINARS IN ONCOLOGY (2012)
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
Mark Levis et al.
BLOOD (2011)
FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML
Keith W. Pratz et al.
BLOOD (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid Leukemia
Amanda F. Cashen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
A Comparison of Azacitidine and Decitabine Activities in Acute Myeloid Leukemia Cell Lines
Paul W. Hollenbach et al.
PLOS ONE (2010)
AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
Patrick P. Zarrinkar et al.
BLOOD (2009)
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C. Flotho et al.
LEUKEMIA (2009)
Mutant FLT3:: A direct target of sorafenib in acute myelogenous leukemia
Weiguo Zhang et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
The C/EBPδ tumor suppressor is silenced by hypermethylation in acute myeloid leukemia
Shuchi Agrawal et al.
BLOOD (2007)
Decitabine and its role in the treatment of hematopoietic malignancies
Elizabeth R. Plimack et al.
LEUKEMIA & LYMPHOMA (2007)
Treatment of acute myelogenous leukemia with outpatient azacitidine
Nimit Sudan et al.
CANCER (2006)
Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBPα expression
R Zheng et al.
BLOOD (2004)
In vitro studies of a FM inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects
M Levis et al.
BLOOD (2004)